السبت 6 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants with Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM) | Eli Lilly and Company | Ongoing | Orforglipron | 3b | J2A-MC-GZPV | 1.King Saud University Medical City - Riyadh 2.Imam Abdulrahman Bin Faisal University - Dammam 3.King Abdulaziz University Hospital - Jeddah 4.King Fahad Specialist Hospital - Dammam |
| A Phase 3,Randomized,Open-Label,Multicenter Study to Compare the Efficacy and Safety of BMS-986393,a GPRC5D-directed CAR-T Cell Therapy,Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma | Celgene Corporation | Ongoing | BMS-986393 | 3 | CA0881007 | 1.King Faisal Specialist Hospital and Research Center - Riyadh |
| A 52-week, multicenter, randomized, double-blind, placebo controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA) | Sanofi | Ongoing | Rilzabrutinib (SAR444671) | 3 | EFC17872 | 1.King Faisal Specialist Hospital and Research Center - Riyadh 2.Prince Mohammed bin Nasser Hospital - Jazan |
| A Real-World, International, MultICentre, Non-Interventional, Prospective CoHORt to Assess the Clinical and Patient-Reported Outcomes in Adults with MOderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated with Breztri/Trixeo (Budesonide /Glycopyrronium / Formoterol) in Routine Care Settings | PI initiated | Ongoing | Budesonide/ Glucopyrronim/ Formoteral | 4 | D5980R0012 | Abha Private Hospital (Asser) ,King Fahad Medical City (Riyadh), Fakeeh Hospital (Jeddah) |
| A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension | Crinetics Pharmaceutical/ Ebkar Consultancy | Ongoing | Atumelnant | 4 | CRN04894-13 | King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Non-Investigational Product, Multi Country Cohort Study to Describe the Long-Term Safety and Effectiveness of a Prior Single-Dose Treatment With Investigative Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Participants With Hemophilia A or Hemophilia B, Respectively | Pfizer Inc. | Ongoing | Giroctocogene Fitelparvovec and Fidanacogene Elaparvovec | 3 | C0371017 | King Faisal Specialist Hospital and Research Center (Riyadh),King Abdallah Medical City (Makkah) |
| A Real-world Multinational Observational Study to Determine Prevalence and Testing Patterns of Mutations in Patients with Hormone Receptor-positive Human Epidermal Growth Factor Receptor 2-negative Advanced or Metastatic Breast Cancer from the Gulf Cooperation Council Countries | AstraZeneca | Ongoing | Capivasertib / Fulvestrant/ Alpelisib | 4 | D133FR0026 | King Fahad Specialist Hospital (Dammam) |
| Comparative, Randomized, Multicenter, Followed by An Open Label Extension Trial in Patients with A Recent Acute Coronary Syndrome Evaluating the Early Inclusion of Inclisiran into Standard of Care Versus Standard of Care Alone in Kingdom of Saudi Arabia | Novartis | Ongoing | Inclisiran | 3 | CKJX839A1S | King Fahad Military Medical Complex (Dharan),King Fahad Armed Forces Hospital (Jeddah), King Fahad Medical City (Riyadh),Prince Sultan Cardiac Center (Riyadh) ,Saud Albabtin Cardiac Center (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxetecan in Patients with HRpositive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated with Endocrine Therapy (BEYOND) | AstraZeneca | Ongoing | Trastuzumab | 4 | D7814R0000 | King Saud University Medical City (Riyadh) |
| A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | ModernaTX, Inc./ Balsam CR | Ongoing | mRNA-3927 | 1/2 | mRNA-3927-P101-EXT | King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.